

## Press Release



EUROPEAN UNION  
Investing in our Future  
European Regional  
Development Fund

### **NMI TT Pharmaservices and Charité awarded grant for development of multiplex protein profiling for individualization of tumor therapy**

Berlin/Germany, June 22, 2017 – Contract research provider NMI TT Pharmaservices and Charité Universitätsmedizin Berlin today announced that they have been awarded a research grant for development of a multiplex protein profiling based platform that aims to improve personalized cancer therapy.

The grant brings together protein profiling specialists of NMI TT Pharmaservices with clinical proteomics experts and molecular pathologists from the Institute of Pathology at Berlin's university hospital Charité, in a two years project that is financed by the ProFIT program of the Investitionsbank Berlin (IBB) and co-funded by the European Regional Development Fund (EFRE) of the European Union.

Under the jointly approved research plan, the NMI TT project team will work with Charité scientists led by Professor Dr. Frederick Klauschen to explore the opportunities of multiplex protein profiling in the individualized optimization of cancer chemotherapy. Specifically, they will establish and validate protocols for protein extraction and multiplex protein profiling of clinical tumor samples, to generate indicative protein panels and protein signatures with the aim to improve targeted therapy prediction in oncology. The backbone of this will be NMI TT Pharmaservices' proprietary DigiWest® protein profiling technology, which allows for parallel analyses of several hundreds of total and phosphoproteins per sample.

Dr. Christoph Sachse, Site Head of NMI TT Pharmaservices' Berlin branch, commented "Given that phosphorylated proteins play an important role in tumor cell signaling, there is increasing evidence that phosphoprotein profiling can add considerable value to the characterization of tumors, beyond the established immunohistochemistry and genomics methods. Within this project, our goal is to further develop our DigiWest® multiplex protein profiling platform such that it will eventually provide medical doctors with better insights into the biology of the individual tumor and thereby facilitate more personalized treatments. We are very pleased to target this challenge together with Professor Klauschen and his colleagues at the renowned Charité Institute of Pathology."

For more details on NMI TT Pharmaservices and its DigiWest® profiling technology, please visit: [www.digiwest.de](http://www.digiwest.de)

For more information on the Institute of Pathology at Charité Universitätsmedizin Berlin, please visit: <https://pathologie-ccm.charite.de>

#### **Contacts**

NMI TT Pharmaservices:  
Dr. Christoph Sachse  
[sachse@nmi-tt.de](mailto:sachse@nmi-tt.de)

Charité Universitätsmedizin Berlin:  
Prof. Dr. Frederick Klauschen  
[frederick.klauschen@charite.de](mailto:frederick.klauschen@charite.de)